Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 12/20 | 0.70 |
| ▸ | ITGA5 | P08648 | 10/20 | 0.70 |
| ▸ | ITGAV | P06756 | 6/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.64 |
| ▸ | ITGA4 | P13612 | 6/20 | 0.61 |
| ▸ | ITGA2 | P17301 | 2/20 | 0.61 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.49 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20975429 | 1.00 | ITGB1 (0.70) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL19412131 | 1.00 | ITGB1 (0.70) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL19426644 | 0.90 | ITGB1 (0.61) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL19426650 | 0.90 | ITGB1 (0.64) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL20975481 | 0.89 | ITGB1 (0.67) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL20975483 | 0.89 | ITGB1 (0.67) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL19412216 | 0.89 | ITGB1 (0.67) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL4254723 | 0.87 | ITGB1 (0.63) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL12084459 | 0.87 | ITGB1 (0.63) | ITGB1ITGA5ITGAVITGB3ITGA4 | |
| SCHEMBL20975486 | 0.87 | ITGB1 (0.69) | ITGB1ITGA5ITGAVITGB3ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144386-A1 | INHIBITORS OF INTEGRIN ALPHA 5 BETA 1 AND METHODS OF USE | ITGA5, ITGB5, ITGB1 | ITGB1 3/4885ITGA5 1/4885ITGAV 15/4885 |
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | ITGA5, ITGB5, ITGB1 | ITGB1 3/4885ITGA5 1/4885ITGAV 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.